Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q14749
UPID:
GNMT_HUMAN
Alternative names:
-
Alternative UPACC:
Q14749; Q5T8W2; Q9NNZ1; Q9NS24
Background:
Glycine N-methyltransferase (GNMT) plays a pivotal role in methyl group metabolism, catalyzing the methylation of glycine to form sarcosine. This process is crucial for regulating the balance between S-adenosyl-L-methionine and S-adenosyl-L-homocysteine, impacting various metabolic pathways.
Therapeutic significance:
GNMT deficiency is linked to mild hepatomegaly and chronic elevation of serum transaminases, highlighting its importance in liver health. Understanding GNMT's role could unveil new therapeutic strategies for managing liver diseases and metabolic disorders.